Author

Maurits F. J. M. Vissers

Observed names: Maurits F.J.M. Vissers, Maurits Vissers

Institution: Centre for Human Drug Research

Observed institutions: Leiden University, Leiden University Medical Center, Centre for Human Drug Research

ORCID: 0000-0001-7199-7301

Observed ORCID: 0000-0001-7199-7301

OpenAlex ID: A5073063590

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

2023 · Danna Jennings, Sarah Huntwork‐Rodriguez, et al. · Movement Disorders · 134

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 ( DNL747 ) for neurodegenerative disorders: Randomized, placebo‐controlled , double‐blind phase I/Ib studies in healthy subjects and patients

2022 · Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, et al. · Clinical and Translational Science · 118

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

2024 · Pepijn Eijsvogel, Pinaki Misra, et al. · Nature Medicine · 63

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

2021 · Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, et al. · International Journal of Molecular Sciences · 25

The impact of the global COVID‐19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis

2020 · Maurits F.J.M. Vissers, Adam F. Cohen, et al. · British Journal of Clinical Pharmacology · 25

Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial

2025 · Brittany N. Flores, Seungyoon B. Yu, et al. · Nature Communications · 24

A leucine‐rich repeat kinase 2 ( LRRK2 ) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls

2023 · Maurits F. J. M. Vissers, Matthew D. Troyer, et al. · Clinical and Translational Science · 16

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

2022 · Manon L. M. Prins, Johan L. van der Plas, et al. · British Journal of Clinical Pharmacology · 10

The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies. (P8-8.010)

2023 · Linus Sun, Richard Tsai, et al. · Neurology · 9

Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism

2022 · Sylvia D. Klomp, Soufian Meziyerh, et al. · Transplant International · 9

Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early‐Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized‐Controlled Trials

2026 · Jannik Rousel, Tessa Niemeyer‐van der Kolk, et al. · Clinical and Translational Science

A Randomized, Double Blind, Placebo-Controlled Study in Patients with Parkinson's Disease with an Alpha-Synuclein Vaccine UB-312

2024 · Pepijn Eijsvogel, Hui-Jing Yu, et al. · SSRN Electronic Journal

Works count: 12

Citation count: 433

H-index: 9

I10-index: 8